Floatz logo

Valspodar

Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)

National Cancer Institute (NCI)protein_peptidePhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) cohort.

Asset / SponsorPhaseRating
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
Fludarabine
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2BBB
Idarubicine
Bruno C. Medeiros
Phase 2BBB
Cytosin-Arabinosid
Alice Mims
Phase 3BBB
ETOPOSIDE
Alice Mims
Phase 3BBB

View all 50 →

Same molecule, other indications

Valspodar is also rated in:

acute erythroid leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
acute megakaryoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
acute myeloid leukemia with minimal differentiationDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →